Identification of hub genes and upstream regulatory factors based on cell adhesion in triple-negative breast cancer by integrated bioinformatical analysis
YH Han, Y Wang, SJ Lee, YY Mao, P Jiang… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: Triple-negative breast cancer (TNBC) is characterized by metastasis and
invasion, as well as poor prognosis, with chemotherapy being the main treatment option …
invasion, as well as poor prognosis, with chemotherapy being the main treatment option …
[HTML][HTML] Construction of circular RNA–MicroRNA–messenger RNA regulatory network of recurrent implantation failure to explore its potential pathogenesis
J Luo, L Zhu, N Zhou, Y Zhang, L Zhang… - Frontiers in …, 2021 - frontiersin.org
Background: Many studies on circular RNAs (circRNAs) have recently been published.
However, the function of circRNAs in recurrent implantation failure (RIF) is unknown and …
However, the function of circRNAs in recurrent implantation failure (RIF) is unknown and …
[HTML][HTML] Gene expression analysis reveals prognostic biomarkers of the tyrosine metabolism reprogramming pathway for prostate cancer
W Li, Z Lu, D Pan, Z Zhang, H He, J Wu, N Peng - Journal of oncology, 2022 - hindawi.com
Background. Tyrosine metabolism pathway-related genes were related to prostate cancer
progression, which may be used as potential prognostic markers. Aims. To dissect the …
progression, which may be used as potential prognostic markers. Aims. To dissect the …
Circ_0035381 regulates acute myeloid leukemia development by modulating YWHAZ expression via adsorbing miR-582-3p
F Xue, M Li, Y Liu, C Xu, H Li, H Liu - Biochemical genetics, 2023 - Springer
Acute myeloid leukemia (AML) is a common hematopoietic disorder. Many circular RNAs
(circRNAs) are abnormally expressed in AML, including hsa_circ_0035381 (circ_0035381) …
(circRNAs) are abnormally expressed in AML, including hsa_circ_0035381 (circ_0035381) …
[HTML][HTML] A network-based integration for understanding racial disparity in prostate cancer
Abstract Compared to Caucasians (CAs), African Americans (AAs) have a higher rate of
incidence and mortality in prostate cancer and are prone to be diagnosed at later stages. To …
incidence and mortality in prostate cancer and are prone to be diagnosed at later stages. To …
Tyrosinase-mediated melanogenesis in melanoma cells: Array comparative genome hybridization integrating proteomics and bioinformatics studies
SJ Yin, JR Lee, MJ Hahn, JM Yang, GY Qian… - International Journal of …, 2021 - Elsevier
We investigated the tyrosinase-associated melanogenesis in melanoma cells by using
OMICS techniques. We characterized the chromosome copy numbers, including Chr 11q21 …
OMICS techniques. We characterized the chromosome copy numbers, including Chr 11q21 …
Design, synthesis and biological activity evaluation of novel covalent S-acylation inhibitors
W Yu, K Yang, M Zhao, H Liu, Z You, Z Liu, X Qiao… - Molecular Diversity, 2023 - Springer
In order to obtain diverse S-acylation inhibitors and address the defects of existing S-
acylation inhibitors, a series of novel covalent S-acylation inhibitors are designed through …
acylation inhibitors, a series of novel covalent S-acylation inhibitors are designed through …
Single nucleotide polymorphisms associated with prostate cancer progression: a systematic review
DF Mendivelso González… - Cancer …, 2024 - Taylor & Francis
Background New biomarkers of progression in patients with prostate cancer (PCa) are
needed to improve their classification and clinical management. This systematic review …
needed to improve their classification and clinical management. This systematic review …
PIM1 Phosphorylation of the Androgen Receptor and 14-3-3 ζ Coordinates Their Interaction and Chromatin Occupancy to Regulate Gene Transcription in Prostate …
S Ruff - 2021 - search.proquest.com
PIM1 is a serine/threonine kinase over-expressed in prostate cancer. It has a variety of
oncogenic roles, including stimulating cell cycle progression, genomic instability, and …
oncogenic roles, including stimulating cell cycle progression, genomic instability, and …
[PDF][PDF] Erythropoietin receptor protects lung cancer cells from chemo-and radiotherapy independent of erythropoietin
L Stadelmann - 2020 - zora.uzh.ch
Erythropoietin (EPO) is used to treat anemia of cancer but is suspected to increase cancer
mortality. EPO is also expressed in hypoxic regions of the tumor and might, thus, contribute …
mortality. EPO is also expressed in hypoxic regions of the tumor and might, thus, contribute …